Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

Figures & data

Table 1 Survival rate with different treatment modalities for HCC

Treatment modality	Survival rate
Surgical resection	90%a
Liver transplant	85% at 4 yearsb
Radiofrequency ablation	63%–81% at 3 yearsc
Transarterial chemoembolization	26% at 3 years
Sorafenib	<10% at 1 year

Notes:

a Very early-stage HCC with nodule <2 cm without vascular or distant metastases.

b Very early-stage HCC meeting Milan Criteria for transplantation.

c Early-stage HCC but not candidates for resection or transplant.

Abbreviation: HCC, hepatocellular carcinoma.

Figure 1 Mechanism of action of tivantinib.

Abbreviations: HGF, hepatocyte growth factor; c-MET, cellular mesenchymal–epithelial transition factor; MAPK, mitogen-activated protein kinase; PKB, protein kinase B; mTOR, mammalian target of rapamycin; PI3K, phophatidylinositol 3-kinase; FAK, focal adhesion kinase.

Table 2 Tumor response to tivantinib in Phase 1B triala

Tumor response	Complete response	Partial response	Stable disease
Patients, n (%)	0	0	9 (56)

Notes:

a Only 16 of 21 patients were able to be evaluated for tumor response. Data from Santoro et al.⁴²

SantoroASimonelliMRodriguez-LopeCA Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosisBr J Cancer20131081212423287988

 PubMed Web of Science ®Google Scholar